Table 2. The effect of HLC-080 and Sorafenib in H22 xenograft model in vivo.

Group	Dose (mmol/kg)	No. of animals(n)	Body Weight (g)		Tumor weight (g)	IR (%)
		Begin/End	Begin	End
Control		10/10	18.16±0.79	27.33±1.87	3.09±0.42
Sorafenib	0.15×4d+0.075×4d	10/10	17.73±0.47	26.29±2.18	1.28±0.40***	58.63
	0.30×4d+0.15×4d	10/5	17.86±0.67	25.02±3.02	1.18±0.45***	61.84
HLC-080	0.15×8d	6/6	18.00±0.54	25.85±2.07	1.98±0.46***	35.81
	0.30×8d	6/6	17.31±0.56	26.56±2.54	2.07±0.59***	33.04

*** P<0.001, compared with control.